Latest period
$27.4M
YoY change
-15.3%
5Y CAGR
-8.9%
Peak year (FY2023)
$56.2M
Latest annual
$20.3M
Total Liabilities history chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: $20.3M
Total Liabilities growth chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -15.3%
Total Liabilities history table for Ovid Therapeutics (OVID) from 2014 to 2025
| FY2025 | $20.3M | -15.3% | -$3.67M | ||
| FY2024 | $23.9M | -57.4% | -$32.3M | ||
| FY2023 | $56.2M | +144.6% | +$33.2M | ||
| FY2022 | $23M | +55.4% | +$8.19M | ||
| FY2021 | $14.8M | -54.2% | -$17.5M | ||
| FY2020 | $32.3M | +198.5% | +$21.5M | ||
| FY2019 | $10.8M | +22.3% | +$1.98M | ||
| FY2018 | $8.84M | +46.9% | +$2.82M | ||
| FY2017 | $6.02M | +61.3% | +$2.29M | ||
| FY2016 | $3.73M | +61.7% | +$1.42M | ||
| FY2015 | $2.31M | +1825.1% | +$2.19M | ||
| FY2014 | $120K | — | — |
- FY2025$20.3M-15.3%
- FY2024$23.9M-57.4%
- FY2023$56.2M+144.6%
- FY2022$23M+55.4%
- FY2021$14.8M-54.2%
- FY2020$32.3M+198.5%
- FY2019$10.8M+22.3%
- FY2018$8.84M+46.9%
- FY2017$6.02M+61.3%
- FY2016$3.73M+61.7%
- FY2015$2.31M+1825.1%
- FY2014$120K—
Total Liabilities values are taken from Ovid Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's latest reported total liabilities is $27.4M. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total liabilities for Ovid Therapeutics (OVID) came in at $20.3M – declined 15.3% year-over-year.
Through 2020–2025 (5 years), Ovid Therapeutics total liabilities delivered a -8.9% annualised rate; with a net decline across the window.
The highest annual total liabilities of $56.2M was reported in 2023. The lowest in the available history was $120K in 2014.
Ovid Therapeutics Total Liabilities by Year
Ovid Therapeutics Total Liabilities 2025: $20.3M
Ovid Therapeutics total liabilities in 2025 was $20.3M, declined 15.3% below 2024.
Ovid Therapeutics Total Liabilities 2024: $23.9M
2024's total liabilities for Ovid Therapeutics came in at $23.9M, plunged 57.4% below 2023.
Ovid Therapeutics Total Liabilities 2023: $56.2M
Ovid Therapeutics posted total liabilities of $56.2M in 2023, surged 144.6% from 2022. This figure represents the highest annual value in the available history.
Ovid Therapeutics Total Liabilities 2022: $23M
In 2022, Ovid Therapeutics reported total liabilities of $23M, surged 55.4% from 2021.
Ovid Therapeutics Total Liabilities 2021: $14.8M
Ovid Therapeutics total liabilities in 2021 was $14.8M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Total Liabilities
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest total liabilities
| $208B | |
| $137B | |
| $118B | |
| $85.9B | |
| $84.2B | |
| $81.9B | |
| $56.8B | |
| $54.9B |
- $137B
- $85.9B
- $84.2B
- $81.9B
- $54.9B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.